ABSTRACT
OBJECTIVE: During short-term treatment, monthly subcutaneous injections of lanreotide Autogel are effective in controlling GH/IGF-1 hypersecretion and are well tolerated in patients with acromegaly. This study reports the effectiveness and the tolerability of lanreotide Autogel for at least 3 years in acromegalic patients. PATIENTS: Fourteen patients (nine females, five males) were treated with titrated doses of lanreotide Autogel. DESIGN: This clinical study was an extension of a previous trial. After three fixed-dose lanreotide Autogel injections, treatment was adjusted according to mean GH and IGF-I levels. After 3 years of treatment, patients were receiving 120 (n=7), 90 (n=2) and 60 mg (n=4) monthly injections of lanreotide Autogel. MEASUREMENTS: Acromegalic symptoms, GH and IGF-1 concentrations were analysed at the end of lanreotide microparticle treatment, and after 4, 8, 12, 24, 30 and 36 months of lanreotide Autogel therapy. Tolerance and side-effects were monitored throughout the 3-year study. RESULTS Hormonal control (GH Subject(s)
Acromegaly/drug therapy
, Peptides, Cyclic/administration & dosage
, Somatostatin/analogs & derivatives
, Delayed-Action Preparations/administration & dosage
, Delayed-Action Preparations/adverse effects
, Drug Administration Schedule
, Female
, Gastrointestinal Diseases/chemically induced
, Hormones/administration & dosage
, Hormones/adverse effects
, Human Growth Hormone/blood
, Humans
, Injections, Subcutaneous/adverse effects
, Insulin-Like Growth Factor I/analysis
, Long-Term Care/methods
, Male
, Middle Aged
, Peptides, Cyclic/adverse effects
, Somatostatin/administration & dosage
, Somatostatin/adverse effects
, Treatment Outcome
